Ivonescimab: Why Did US FDA Reject China's Promising Lung Cancer Drug?

Ivonescimab: Why Did The US FDA Reject China's Promising Lung Cancer Drug?

Credit: iStock

Text

Updated Nov 16, 2026 | 10:51 AM IST

SummaryThe FDA's decision came after a late-stage clinical trial showed that ivonescimab significantly delayed disease progression but failed to demonstrate a statistically significant improvement in overall survival (OS), a key measure of how long patients live after starting treatment.

End of Article